Summary: New research identifies the protein TIMP3 as being overproduced in age-related macular degeneration (AMD) and implicates it in early disease processes. By targeting downstream inflammation pathways and enzymes tied to drusen formation, scientists reduced early AMD features in human stem cell models, pointing to promising new therapeutic directions.
Current treatments for AMD are limited in scope and effectiveness. This study sheds light on molecular mechanisms that drive drusen accumulation and inflammation in the retinal pigment epithelium (RPE), suggesting targeted strategies to slow or prevent vision loss.
Key Facts:
- TIMP3 overproduction is associated with early-stage AMD and related macular dystrophies.
- Reduced activity of RPE-secreted MMP2 contributes to inflammation and drusen formation.
- Blocking the RAGE-sPLA2-IIA inflammatory axis or supplementing MMP2 reduced drusen in human iPSC-derived RPE models.
- These findings point to potential therapeutic targets to prevent AMD progression and preserve vision.
Source: University of Rochester
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in the United States, and effective, well-tolerated therapies remain scarce. New work published in Developmental Cell uses human induced pluripotent stem cell (iPSC) models to reveal a mechanistic pathway that drives drusen formation and inflammation in AMD and several related macular dystrophies.
“Existing treatments for AMD can be limited and sometimes have substantial side effects,” said Ruchira Singh, PhD, of the University of Rochester Flaum Eye Institute and Center for Visual Sciences, and the study’s lead author. “Our goal was to identify targets that could halt the disease before irreversible vision loss occurs.”
The research team modeled AMD using human iPSC-derived retinal pigment epithelium (RPE) cells from patients with AMD and from individuals with three different inherited macular dystrophies. These human cell models avoid some limitations of animal studies and allow direct investigation of human RPE biology, including how drusen—lipid- and protein-rich deposits beneath the RPE—form and accumulate over time.
The investigators identified elevated levels of TIMP3, a tissue inhibitor of metalloproteinases, in disease models. TIMP3 suppresses matrix metalloproteinases (MMPs), notably MMP2, which are enzymes that maintain extracellular matrix and lipid homeostasis in the RPE. When MMP2 activity is reduced, the team observed downstream effects that promote sterile inflammation: release of damage-associated molecular patterns (DAMPs), activation of the receptor for advanced glycation end-products (RAGE), and increased levels of secreted phospholipase A2-IIA (sPLA2-IIA), an enzyme that contributes to inflammatory signaling and lipid alterations.
Importantly, the study explored several therapeutic interventions in the human RPE models. Restoring MMP2 activity specifically in the RPE, applying a RAGE-antagonistic peptide, and using a small-molecule inhibitor of sPLA2-IIA each reduced drusen accumulation in the iPSC-derived RPE cells. These complementary approaches support a causal role for a MMP2–DAMP–RAGE–sPLA2-IIA axis in driving drusen formation across multiple genotypes.
“Our data indicate that cellular pathways that produce drusen are central drivers of AMD progression,” Dr. Singh said. “If we can interrupt these pathways—by restoring MMP2 function or by blocking the inflammatory cascade that follows—we may be able to stop the disease before it advances to vision-threatening stages.”
The study’s multi-institutional author list includes Sonal Dalvi, Michael Roll, Amit Chatterjee, Lal Krishan Kumar, Akshita Bhogavalli, Nathaniel Foley, Cesar Arduino, Whitney Spencer, Cheyenne Reuben-Thomas, Davide Ortolan, Kapil Bharti, Alice Pebay, and Bela Anand-Apte, among others. Funding came from the National Eye Institute, the ForeBatten Foundation, and Research to Prevent Blindness.
About this AMD, vision, and genetics research news
Author: Mark Michaud
Source: University of Rochester
Contact: Mark Michaud – University of Rochester
Image credit: Neuroscience News
Original research (open access): Human iPSC-based disease modeling studies identify a common mechanistic defect and potential therapies for AMD and related macular dystrophies by Ruchira Singh et al., published in Developmental Cell.
Abstract
Human iPSC-based disease modeling studies identify a common mechanistic defect and potential therapies for AMD and related macular dystrophies
Age-related macular degeneration (AMD) and related macular dystrophies primarily affect the retinal pigment epithelium (RPE). A hallmark that drives disease progression is drusen—sub-RPE, lipid-protein-rich extracellular deposits. How drusen form and accumulate has been unclear.
Using iPSC-derived RPE from patients with AMD and three distinct macular dystrophies, the researchers show that reduced activity of RPE-secreted matrix metalloproteinase 2 (MMP2) contributes to drusen by triggering sterile inflammation and disrupting lipid homeostasis. This occurs via DAMP-mediated activation of RAGE and increased levels of sPLA2-IIA. Therapeutically, RPE-specific MMP2 supplementation, a RAGE-antagonistic peptide, and a small-molecule inhibitor of sPLA2-IIA each reduced drusen accumulation in the iPSC-RPE models.
Overall, the study defines a causal role for the MMP2–DAMP–RAGE–sPLA2-IIA axis in AMD and related maculopathies and highlights actionable targets for future therapies aimed at preventing vision loss by stopping drusen accumulation and the inflammatory cascade that follows.